Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib window study in high-risk endometrial cancer
NCT05320757Phase 1Completed
- Sponsor
- The University of Hong Kong
- Start
- Apr 2022
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of olaparib in endometrial cancer (EC), sponsored by The University of Hong Kong. Primary endpoint: Extent of DNA damage up to 18 months. Started Apr 2022; status: completed.
02
Drugs
olaparib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT05320757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05320757.